38 results about "Bipolar I disorder" patented technology

The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.

The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist) and an antipsychotic drug. This combination can reduce metabolic side effects which appear if using an antipsychotic drug alone.

The present invention relates to the use of bombesin / gastrin releasing peptide antagonist in the preparation of pharmaceutical composition, said pharmaceutical composition is used for treating inflammatory diseases and immune-mediated inflammatory diseases, especially sepsis , acute lung injury and rheumatoid arthritis and for the treatment or prevention of brain disorders, preferably bipolar disorders, and in particular of different types and / or subtypes of bipolar disorders such as mania, acute mania, Severe mania, hypomania, depression, moderate depression, dysthymia, major depressive disorder, manic and / or depressive episodes, psychotic / psychotic symptoms (e.g., hallucinations, delusions), mixed bipolar states, Bipolar I disorder, bipolar II disorder, and / or rapid cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides such as gastrin-releasing peptide can be used in the treatment of inflammatory and immune-mediated inflammatory diseases and brain disorders .

The present invention relates to methods with 3-arylthioindole-2-carboxamides, 5-substituted-3-arylthioindole-2-carboxamides and related analogues for treating a patient suffering from diseases or disorders of the central nervous system associated with the disturbance of the human circadian clock that are ameliorated by inhibition of casein kinase Ie activity such as , for example, mood disorders including major depressive disorder, bipolar I disorder and bipolar II disorder, and sleep disorders including circadian rhythm sleep disorders such as, for example, shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome.

Described herein is a method of determining lithium responsiveness in a bipolar disorder patient. The method includes obtaining a sample from a patient having bipolar disorder, and assaying the sample for the presence or absence of one or more glutamate decarboxylase-like 1 (GADL1) gene variants selected from the group consisting of a T allele of the single nucleotide polymorphism (SNP) rs17026688, a G allele of the SNP rs17026651, and GADL1 1VS8+48delG. The presence of one or more of the GADL1 gene variants indicates that the patient is responsive to lithium treatment.

The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+ / CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway. Methods of identifying a compound that modulates DAG and its related enzymes along the DAG signaling pathway are provided. These compounds decrease or increase the membrane potential ratio (MPR™) in BD and ADHD patients.

Methods for detecting resistance to sedation caused by antipsychotic drugs including methods for detecting psychotic disorders such as but not limited to schizophrenia or bipolar I disorder featuring administering to a patient a dose of an antipsychotic medication; and subjecting the patient to an evaluation at a time point following administration of the dose of the antipsychotic medication. The evaluation is adapted to determine a level of sedation resulting from the dose of the antipsychotic medication. A resulting level of sedation may be one of the following: completely sedated, significantly sedated, moderately sedated, not significantly sedated and completely alert. If the individual is not completely sedated or significantly sedated, or is completely alert, then the patient may have a likelihood of having a psychotic disorder such as schizophrenia.